Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer
- 8 May 2003
- journal article
- Published by Wiley in The Prostate
- Vol. 56 (1) , 23-29
- https://doi.org/10.1002/pros.10239
Abstract
Backgrounds The present study was designed to identify the preoperative parameters, including PSA‐based parameters, and endorectal MRI, predictive of pathological stage in males who underwent radical prostatectomy. Methods We studied 114 patients who underwent radical retropubic prostatectomy and pelvic lymphadenectomy for clinically localized prostate cancer. Clinical stage was assessed by DRE, pelvic CT scan, endorectal MRI, and bone scan. The correlation between the preoperative parameters, including PSA‐based parameters, clinical stage, and histological findings of biopsy specimens, and the pathological stage was analyzed. Logistic regression analysis was performed to identify a significant set of independent predictors for local extent of disease. Results Seventy‐six (66.6%) patients had organ confined cancer and 38 (33.4%) patients had extraprostatic cancer. Of the 38 patients with extraprostatic cancer, four had seminal vesicle involvement, while, none had pelvic lymph node involvement. Biopsy Gleason score, PSA, PSA‐α1‐antichymotrypsin (PSA‐ACT), PSA‐density (PSAD), PSA‐transition zone density, PSA‐ACT density, and PSA‐ACT transition zone (TZ) density were significantly higher and percent free PSA was lower in the patients with organ confined cancer than those with extraprostatic cancer (P < 0.01). PSAD showed the largest area under the ROC curve (AUC) among those parameters (AUC = 0.732). Sixty‐eight (74.7%) of 91 patients with T2 on endorectal MRI had organ confined cancer, while 15 (65.2%) of 23 patients with T3 had extraprostatic cancer (P < 0.01). Multivariate logistic regression analysis indicated that Gleason score (≥7 vs. ≤6), endorectal MRI findings, and PSAD were significant predictors of extraprostatic cancer (P < 0.01). Conclusions The present study demonstrated that preoperative PSAD was the most valuable predictor among PSA‐based parameters for extraprostatic disease in patients with clinically localized prostate cancer. The combination of PSAD, endorectal MRI findings, and biopsy Gleason score can provide additional information for selecting appropriate candidates for radical prostatectomy. Prostate 56: 23–29, 2003.Keywords
This publication has 24 references indexed in Scilit:
- Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trialUrology, 2002
- CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTSJournal of Urology, 2002
- Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millenniumUrology, 2001
- A CATALOG OF PROSTATE CANCER NOMOGRAMSJournal of Urology, 2001
- VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2000
- Complications after radical retropubic prostatectomy in the medicare populationUrology, 2000
- PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOINGJournal of Urology, 1999
- Review of staging modalities in clinically localized prostate cancerUrology, 1999
- Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate CancerJAMA, 1997
- The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate CancerJournal of Urology, 1993